GLP-1 treatments are here to stay, and investment in them is only growing. As these treatments become a phenomenon, agencies are creating dedicated departments to deepen their understanding and focus on GLP-1s. But how do you navigate the vast amount of conversational data surrounding GLP-1s? The solution is straightforward – Drug-GPT.
Discover what real-life Consumer conversations reveal about the evolving GLP-1 journey, from dose adjustments and weight loss plateaus to discontinuation, persistence, and the branded vs compounded debate.
Quickly solving a problem. Using real-life health related data to inform strategy. Shift from planning assumptions to real-life intelligence – powered by behavior, sentiment and engagement data.
Can large language models truly support regulatory-grade pharmaceutical communication? Learn more in our recent TMLabs briefing session.